Holen Sie sich die Stockscreener-App
1.40
1.41%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.42
Offen:
$1.39
24-Stunden-Volumen:
2.61M
Relative Volume:
0.55
Marktkapitalisierung:
$277.48M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.6604
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-7.28%
1M Leistung:
+40.00%
6M Leistung:
-21.79%
1J Leistung:
-35.78%
1-Tages-Spanne:
$1.3435
$1.42
1-Wochen-Bereich:
$1.3435
$1.74
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.40 | 281.44M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
What is the dividend policy of Esperion Therapeutics Inc. stockInvest smarter with data-backed trading alerts - jammulinksnews.com
Is Esperion Therapeutics Inc. a good long term investmentStay ahead with advanced stock screening tools - jammulinksnews.com
Esperion Therapeutics Inc. Stock Analysis and ForecastCapitalize on stocks with high profit margins - jammulinksnews.com
What are Esperion Therapeutics Inc. company’s key revenue driversExceptional trading performance - jammulinksnews.com
Is Esperion Therapeutics Inc. stock overvalued or undervaluedExceptional market positioning - jammulinksnews.com
How does Esperion Therapeutics Inc. compare to its industry peersFree Stock Outlook That Work - jammulinksnews.com
Esperion Therapeutics soars amid vague takeover speculation - MSN
Is Esperion Therapeutics Inc. a growth stock or a value stockBeginner Investor Opportunities To Watch Now - jammulinksnews.com
What is the risk reward ratio of investing in Esperion Therapeutics Inc. stockRetirement Planning Report With Low Risk - jammulinksnews.com
Should I hold or sell Esperion Therapeutics Inc. stock in 2025Wealth Building Review That Work - jammulinksnews.com
What are the latest earnings results for Esperion Therapeutics Inc.Free Stock Alerts For Every Investor - jammulinksnews.com
What institutional investors are buying Esperion Therapeutics Inc. stockReal Time Watchlist With Proven Results - jammulinksnews.com
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Investment Strategy With Predictable Gains Outlined - metal.it
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors - MSN
What makes Esperion Therapeutics Inc. stock price move sharplyMarket Entry and Exit Point Tips From Traders - metal.it
How many analysts rate Esperion Therapeutics Inc. as a “Buy”Expert guidance for superior capital growth - jammulinksnews.com
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025 Profit Target Planning with Exit Confidence - metal.it
Why is Esperion Therapeutics Inc. stock attracting strong analyst attentionRapidly growing investment returns - jammulinksnews.com
How strong is Esperion Therapeutics Inc. company’s balance sheetUnlock powerful portfolio management tools - jammulinksnews.com
What analysts say about Esperion Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Esperion Therapeutics Shares Surge 19% Amid Rumors - AInvest
Is Esperion Therapeutics Inc. stock a good hedge against inflationFree Popular Stock Recommendations - jammulinksnews.com
Esperion Therapeutics Surges: Can This Momentum Last? - StocksToTrade
Esperion Therapeutics soars amid vague takeover speculation (ESPR:NASDAQ) - Seeking Alpha
Esperion Therapeutics to Release Q2 2025 Financial Results and Host Webcast on August 5 - AInvest
Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative
Esperion to Report Second Quarter 2025 Financial Results on August 5 - The Manila Times
What drives Esperion Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):